Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

P.O. BOX 125, Stewartsville, United States

hiTHit Aug. 19 at 3:19 PM

$VYNE hanging man candle

0 · Reply

hiTHit Aug. 10 at 5:10 PM

$VYNE Replace the 11,111 people here. The current 11,111 people would have to leave, and then a new group of 11,111 people would have to join... I think if NVDA had bought this company, the number of watchers would still be 11,111.🤓

1 · Reply

hiTHit Aug. 7 at 5:14 PM

$VYNE If the fair value is $6.56, I recommend that novice investors like me track price movements to gain experience even without buying.

0 · Reply

phaa Aug. 6 at 10:12 PM

$VYNE LOL, So Yarrow Science that was a private clinical stage biotech before going public with a reverse merger with VYNE..... I called this 5 years ago. Good luck to anyone investing in this. Do your due diligence. Look up Foamix and their merger, look up VYNE and their history. Do you due diligence

2 · Reply

hiTHit Aug. 5 at 5:21 PM

$VYNE My dear money, is something wrong between us? If so, I’m sorry. Please come back to me. Let’s start over from the beginning.🤓

1 · Reply

hiTHit Aug. 3 at 5:17 PM

$VYNE Despite its low daily trading volume, it became such a highly manipulative stock that...

3 · Reply

stocktwitney Aug. 2 at 4:12 PM

$VYNE did anyone else just get a notification from Robinhood that their dividend was reversed? I held through this week. Sold a couple of days ago

1 · Reply

beppels Jul. 31 at 7:35 AM

$LFS BEPPELS WL 31.07.: - $LFS, 2.65 $, halted up in overnite, 12.5 mln float, 1110 % ctb, 0 shares to borrow, I ve called this japan gem many times as top swing, today we ll get rewarded! News are overdue, last pr was 2 weeks ago and they normally put out news every few days! Top watch today! ✅ - $NIKI, 10 $, 1.17 mln float, china bio merger from $APM.X with 51 % 13 d! ✅ - $YARW, 33 $, 600 k float, 43 $ cash per share, merger with $VYNE, climbing for days, slow and steady! ✅ Also watch $KUST, CYCU, TC and BRAI! 👀 🔥 👀

0 · Reply

Rulaxx1574 Jul. 30 at 12:56 AM

$VYNE did Yarrow dump the CEO from hell, Dumbzalski?

0 · Reply

DarvasBoxing Jul. 29 at 7:52 PM

$VYNE wen Yarrow?

1 · Reply

VYNE Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

VYNE Therapeutics Earnings release: Q2 2026

Jul 14, 2026, 7:00 AM EDT - 5 weeks ago

VYNE Therapeutics Slides: Investor presentation

May 15, 2026, 7:00 AM EDT - 3 months ago

VYNE Therapeutics Quarterly report: Q1 2026

Feb 27, 2026, 7:00 AM EST - 6 months ago

VYNE Therapeutics Annual report: Q4 2025

Dec 17, 2025, 8:30 AM EST - 8 months ago

VYNE Therapeutics Transcript: M&A Announcement

Dec 17, 2025, 8:30 AM EST - 8 months ago

VYNE Therapeutics Press release: M&A Announcement

Nov 12, 2025, 7:00 AM EST - 10 months ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 6, 2025, 8:00 AM EST - 10 months ago

VYNE Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

VYNE Therapeutics Earnings release: Q3 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Earnings release: Q2 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Earnings release: Q1 2025

Mar 27, 2025, 11:00 AM EDT - 1 year ago

VYNE Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Annual report: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 11:10 AM EST - 1 year ago

VYNE Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Nov 12, 2024, 7:00 AM EST - 1 year ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q3 2024

Sep 17, 2024, 8:30 AM EDT - 2 years ago

VYNE Therapeutics Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q2 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q1 2024

Mar 1, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Registration statement: Registration Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Annual report: Q4 2023

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Earnings release: Q4 2023

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Registration statement: Registration Filing

Nov 13, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 9, 2023, 1:30 PM EST - 3 years ago

VYNE Therapeutics Transcript: R&D Day 2023

Nov 9, 2023, 1:30 PM EST - 3 years ago

VYNE Therapeutics Slides: FY 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q2 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q1 2023

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Annual report: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Earnings release: Q4 2022

Nov 25, 2022, 7:00 AM EST - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 14, 2022, 7:00 AM EST - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 10, 2022, 7:00 AM EST - 4 years ago

VYNE Therapeutics Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 4 years ago

VYNE Therapeutics Earnings release: Q3 2022

Aug 12, 2022, 7:00 AM EDT - 4 years ago

VYNE Therapeutics Quarterly report: Q2 2022

Aug 12, 2022, 7:00 AM EDT - 4 years ago

VYNE Therapeutics Earnings release: Q2 2022

Jul 28, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jul 19, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jul 7, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 17, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 7, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

May 17, 2022, 10:00 AM EDT - 4 years ago

VYNE Therapeutics Slides: FY 2022

May 12, 2022, 7:00 AM EDT - 4 years ago

VYNE Therapeutics Quarterly report: Q1 2022

May 12, 2022, 7:00 AM EDT - 4 years ago

VYNE Therapeutics Earnings release: Q1 2022

Mar 17, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Annual report: Q4 2021

Mar 17, 2022, 8:00 AM EDT - 4 years ago

VYNE Therapeutics Earnings release: Q4 2021

Nov 10, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Earnings Call Transcript: Q3 2021

Nov 10, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Quarterly report: Q3 2021

Nov 10, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Earnings release: Q3 2021

Nov 10, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Slides: Q3 2021

Aug 12, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Earnings Call Transcript: Q2 2021

Aug 12, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Quarterly report: Q2 2021

Aug 12, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Earnings release: Q2 2021

Jun 29, 2021, 8:00 AM EDT - 5 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 7, 2021, 8:00 AM EDT - 5 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 7, 2021, 8:00 AM EDT - 5 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

May 26, 2021, 8:00 AM EDT - 5 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

May 6, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Earnings Call Transcript: Q1 2021

May 6, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Quarterly report: Q1 2021

May 6, 2021, 8:30 AM EDT - 5 years ago

VYNE Therapeutics Earnings release: Q1 2021

May 6, 2021, 8:00 AM EDT - 5 years ago

VYNE Therapeutics Registration statement: Registration Filing

Mar 4, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Earnings Call Transcript: Q4 2020

Mar 4, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Annual report: Q4 2020

Mar 4, 2021, 8:30 AM EST - 5 years ago

VYNE Therapeutics Earnings release: Q4 2020

Nov 5, 2020, 8:30 AM EST - 6 years ago

VYNE Therapeutics Earnings Call Transcript: Q3 2020

Nov 5, 2020, 8:30 AM EST - 6 years ago

VYNE Therapeutics Quarterly report: Q3 2020

Nov 5, 2020, 8:30 AM EST - 6 years ago

VYNE Therapeutics Earnings release: Q3 2020

Oct 1, 2020, 12:00 PM EDT - 6 years ago

VYNE Therapeutics Transcript: Investor Update

Oct 1, 2020, 12:00 PM EDT - 6 years ago

VYNE Therapeutics Slides: Investor Update

Sep 9, 2020, 8:00 AM EDT - 6 years ago

VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September

Sep 8, 2020, 8:01 AM EDT - 6 years ago

Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

Aug 6, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Earnings Call Transcript: Q2 2020

Aug 6, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Quarterly report: Q2 2020

Aug 6, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Earnings release: Q2 2020

Jul 14, 2020, 8:00 AM EDT - 6 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 22, 2020, 8:00 AM EDT - 6 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 22, 2020, 8:00 AM EDT - 6 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 10, 2020, 8:00 AM EDT - 6 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Jun 5, 2020, 7:00 AM EDT - 6 years ago

Menlo Therapeutics Announces Pricing of Offering of Common Stock

Jun 4, 2020, 4:01 PM EDT - 6 years ago

Menlo Therapeutics Announces Proposed Offering of Common Stock

May 29, 2020, 11:49 AM EDT - 6 years ago

Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

May 29, 2020, 11:38 AM EDT - 6 years ago

Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

May 11, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Earnings Call Transcript: Q1 2020

May 11, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Quarterly report: Q1 2020

May 11, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Earnings release: Q1 2020

Apr 23, 2020, 8:00 AM EDT - 6 years ago

Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China

Apr 6, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Transcript: Study Result

Apr 6, 2020, 7:00 AM EDT - 6 years ago

Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis

Apr 2, 2020, 8:00 AM EDT - 6 years ago

Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues

Mar 24, 2020, 8:00 AM EDT - 6 years ago

Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

Mar 20, 2020, 8:00 AM EDT - 6 years ago

Menlo Therapeutics Provides a Business Update in the Context of COVID-19

Mar 12, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Transcript: M&A Announcement

Mar 12, 2020, 8:30 AM EDT - 6 years ago

VYNE Therapeutics Press release: M&A Announcement

Mar 9, 2020, 8:00 AM EDT - 7 years ago

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Mar 3, 2020, 7:00 AM EST - 7 years ago

VYNE Therapeutics Annual report: Q4 2019

Mar 3, 2020, 7:00 AM EST - 7 years ago

VYNE Therapeutics Earnings release: Q4 2019

Feb 26, 2020, 8:06 AM EST - 7 years ago

Menlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goals

Feb 26, 2020, 7:30 AM EST - 7 years ago

Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

Feb 5, 2020, 8:30 AM EST - 7 years ago

Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology

Jan 22, 2020, 3:16 PM EST - 7 years ago

Steven Cohen’s Point72 Piles Into Menlo Therapeutics

Nov 11, 2019, 8:30 AM EST - 7 years ago

VYNE Therapeutics Earnings Call Transcript: Q3 2019

Nov 11, 2019, 8:30 AM EST - 7 years ago

VYNE Therapeutics Quarterly report: Q3 2019

Nov 11, 2019, 8:30 AM EST - 7 years ago

VYNE Therapeutics Earnings release: Q3 2019

Nov 11, 2019, 8:30 AM EST - 7 years ago

VYNE Therapeutics Slides: Q3 2019

Nov 11, 2019, 8:00 AM EST - 7 years ago

Menlo, Foamix stocks set for selloffs after all-stock merger deal

Nov 11, 2019, 6:00 AM EST - 7 years ago

Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

Oct 29, 2019, 7:00 AM EDT - 7 years ago

Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

Oct 22, 2019, 8:30 AM EDT - 7 years ago

Menlo Therapeutics to Host Investor Day October 29, 2019

Oct 11, 2019, 8:30 AM EDT - 7 years ago

Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

Sep 26, 2019, 4:05 PM EDT - 7 years ago

Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Sep 24, 2019, 4:05 PM EDT - 7 years ago

Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

Aug 29, 2019, 4:05 PM EDT - 7 years ago

Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

hiTHit Aug. 19 at 3:19 PM

$VYNE hanging man candle

0 · Reply

hiTHit Aug. 10 at 5:10 PM

1 · Reply

hiTHit Aug. 7 at 5:14 PM

$VYNE If the fair value is $6.56, I recommend that novice investors like me track price movements to gain experience even without buying.

0 · Reply

phaa Aug. 6 at 10:12 PM

2 · Reply

hiTHit Aug. 5 at 5:21 PM

$VYNE My dear money, is something wrong between us? If so, I’m sorry. Please come back to me. Let’s start over from the beginning.🤓

1 · Reply

hiTHit Aug. 3 at 5:17 PM

$VYNE Despite its low daily trading volume, it became such a highly manipulative stock that...

3 · Reply

stocktwitney Aug. 2 at 4:12 PM

$VYNE did anyone else just get a notification from Robinhood that their dividend was reversed? I held through this week. Sold a couple of days ago

1 · Reply

beppels Jul. 31 at 7:35 AM

0 · Reply

Rulaxx1574 Jul. 30 at 12:56 AM

$VYNE did Yarrow dump the CEO from hell, Dumbzalski?

0 · Reply

DarvasBoxing Jul. 29 at 7:52 PM

$VYNE wen Yarrow?

1 · Reply

hiTHit Jul. 29 at 5:42 PM

$VYNE What successes has this company achieved that justify its stock price of $30?

2 · Reply

focafoca99 Jul. 28 at 9:30 PM

$VYNE merged with Yarrow Bioscience, completing a tax-free reorganization and changing its name to Yarrow Bioscience, Inc.

0 · Reply

JRR21 Jul. 28 at 7:46 PM

$VYNE there is no volume today? When will trade new yarw exvyne shares?

0 · Reply

hiTHit Jul. 28 at 3:16 PM

$VYNE In your opinion, how many reverse splits will YARROW undergo, and when will the price drop below $1?

0 · Reply

topstockalerts Jul. 28 at 12:31 AM

$VYNE buyers are treating every dip like an invitation.

1 · Reply

TwongStocks Jul. 27 at 8:34 PM

Today's reverse split results: $AMZE 1 for 8. Previous close $0.0924, $0.7392 split-adjusted Today's high $0.73 (premarket) Today's close $.3068 🔴Down 58.50% $SGLY 1 for 14 Previous close $0.2686, $3.7604 split-adjusted Today's high $4.42 Today's close $4.01 🟢Up 6.64% $STKH 1 for 3 Previous close $0.4226, $1.2678 split-adjusted Today's high $1.60 Today's close $1.35 🟢Up 6.48% $VYNE 1 for 50 Previous close $0.5090, $25.45 split-adjusted Today's high $28.56 Today's close $28.56 🟢Up 12.22% $ZNB 1 for 8 Previous close $0.2800, $2.24 split-adjusted Today's high $2.85 Today's close $2.69 🟢Up 20.09%

0 · Reply

TwongStocks Jul. 27 at 7:15 PM

$VYNE Equity Corporate Actions Alert #2026 - 527 Information Regarding the Business Combination of VYNE Therapeutics Inc. (VYNE) and Yarrow Bioscience, Inc. https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-527 The business combination of VYNE Therapeutics Inc. (VYNE) and Yarrow Bioscience, Inc. closed today, Monday, July 27, 2026. Following the completion of the business combination, the company's Common stock will undergo a name and symbol change. These actions will become effective on Tuesday, July 28, 2026. Current Company Name & Issue Type: VYNE Therapeutics Inc. Common Stock New Company Name & Issue Type: Yarrow Bioscience, Inc. Common Stock CUSIP: 92941V407 Current Symbol: VYNE New Symbol: YARW Marketplace Effective Date: July 28, 2026

0 · Reply

hiTHit Jul. 27 at 4:09 PM

$VYNE Current actual price: ($0.5 ÷ 1/50 RS) ÷ 1/18 RS = $0.0005 In a few months, the sign will show 9 USD; in a few years, you’ll see a price below 1 USD…

1 · Reply

TwongStocks Jul. 27 at 11:26 AM

$AMZE $SGLY $STKH $VYNE $ZNB all have reverse splits today. Trading will resume at 9:00am ET with the RS in effect. Full details in the quoted post.

0 · Reply

DarvasBoxing Jul. 26 at 3:25 PM

$VYNE seeing different news. Doesn’t all match my account yet but it does for one. one account shows yarrow and one account shows VYNE. My dividends paid out on both.

0 · Reply

FreeBeerTomorrow Jul. 26 at 9:44 AM

$VYNE VYNE Therapeutics (VYNE) is scheduled to begin trading on a split-adjusted basis this coming Monday, July 27, 2026. Ratio: 1-for-50 reverse split. Pre-Split Outstanding Shares: ~33.4 million to 43 million shares (including equivalents). Post-Split Outstanding Shares: Approximately 670,000 to 860,000 shares following the 1-for-50 reduction. Estimated Public Float: Stripping out institutional/insider restricted holdings, the standalone tradeable float on Monday is estimated to be extremely tight—roughly 600,000 to 750,000 shares.

2 · Reply

RevenantTrading Jul. 25 at 11:29 PM

$CCHH Hot watch for next week, this can launch big with news due. CCHH very small float too! R/s tickers for Monday: $VYNE $SGLY $ZNB $STKH

0 · Reply

Market Cap	19.07M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,645.61%
Debt to Equity Ratio	0.00

Volume	93,200
Avg Vol	19,332
Day's Range	N/A - N/A
Shares Out	668,000.00
Stochastic %K	22%
Beta	2.00
Analysts	Hold
Price Target	$2.00